A report from China Daily https://mma.prnewswire.com/media/2801343/Image.jpg China has made remarkable progress in systemic governance for its green transition, with even more expected during the upcoming 15th Five-Year Plan period (2026-30), according to international experts. On Thursday, experts and officials from the China Council for International Cooperation on Environment and Development gathered in Beijing to share […]

Good growth and strong margin Third quarter — Net sales totaled SEK 38,146 M (37,418), with organic growth of 3% (0) and acquired net growth of 5% (4). Exchange rates affected sales by -6% (-3). — Organic sales growth was good in EMEIA, Entrance Systems, Global Technologies and Americas, while organic sales declined in Asia

CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3G Eleva successfully completed the Single Ascending Dose part of the First-in-Human clinical trial evaluating CPV-104 in healthy volunteers The Safety Review Committee endorsed the study with no safety concerns identified across all four dose cohorts 18

LingoAce has been named to the 2026 GSV 150, earning milestone recognition as one of the world's most transformational growth companies in digital learning and workforce skills-marking the third time the company has received this honor. Using a proprietary rubric-including revenue scale, revenue growth, user reach, geographic diversification, and margin profile-GSV evaluated more than 3,000

“We demonstrated strength in the third quarter with significant organic growth, improved profitability and cash flow despite impacts from tariffs and negative currency effects,” says Mattias Perjos, President & CEO, Getinge. The medtech company's net sales increased organically by 9,5% while order intake rose by 4,7% organically. Acute Care Therapies continued to meet the higher

Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers GlobeNewswire October 21, 2025 CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3G Eleva successfully completed the Single Ascending Dose part

Bringing together more than 50 market and craft experts and researchers from 12 countries around the world Researching Cheongju as a best practice for a craft-based experiential economy Administrative and cultural experts from around the world will gather in Cheongju, a city in the Republic of Korea that is currently hosts the Cheongju Craft Biennale

On October 21, 2025, the 2025Chery International User summit – a global gathering transcending geography and culture – was grandly held in Wuhu, China.With the theme “Co-Create, Co-Define,” the event brought together more than 3,000 participants from nearly 100 countries, including overseas users, dealership partners, members of the ESG Advisory Alliance, and international media representatives,

LONDON, GB / ACCESS Newswire / October 21, 2025 / Physitrack PLC (STO:PTRK) – Fourth Consecutive Quarter of Resilient, Cash-Generative Growth, Marking Historical Positive Cash flow. Investor snapshot Metric Q3 2025 Q3 2024 YoY D Q2 2025 QoQ D Revenue (Pro forma) €m 3.5 3.3 6% 3.5 -2% Constant currency revenue €m 3.6 3.3 9%

DOUGLAS, ISLE OF MAN, GB / ACCESS Newswire / October 21, 2025 / Agronomics (LSE:ANIC), the leading listed company in the field of clean food, is pleased to announce that its portfolio company Geltor, Inc. ("Geltor") has received a ‘No Questions’ Letter from the US Food and Drug Administration ("FDA"), confirming the Generally Recognized As